Suzanne D. Burke

Suzanne D. Burke

Auto-generated profile, based on publicly available information

Suzanne D. Burke

Department of Anatomy and Cell Biology, Queen's University, Kingston, ON K7L 3N6, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2012 in Nature
Verified
Journal Article
Open access
PDF file
IPIan S. Patten
Ian S. Patten
SRSarosh Rana
Sarosh Rana
SSSajid Shahul
Sajid Shahul
GRGlenn C. Rowe
Glenn C. Rowe
CJCholsoon Jang
Cholsoon Jang
ZAZoltan Arany
Zoltan Arany
Peripartum cardiomyopathy (PPCM) is an often fatal disease that affects pregnant women who are near delivery, and it occurs more frequently in women with pre-eclampsia and/or multiple gestation. The aetiology of PPCM, and why it is associated with pre-eclampsia, remain unknown. Here we show that PPCM is associated with a systemic angiogenic imbalance, accentuated by pre-eclampsia. Mice that lack cardiac PGC-1α, a powerful regulator of angiogenesis, develop profound PPCM. Importantly, the PPCM is entirely rescued by pro-angiogenic therapies. In humans, the placenta in late gestation secretes VEGF inhibitors like soluble FLT1 (sFLT1), and this is accentuated by multiple gestation and pre-eclampsia. This anti-angiogenic environment is accompanied by subclinical cardiac dysfunction, the extent of which correlates with circulating levels of sFLT1. Exogenous sFLT1 alone caused diastolic dysfunction in wild-type mice, and profound systolic dysfunction in mice lacking cardiac PGC-1α. Finally, plasma samples from women with PPCM contained abnormally high levels of sFLT1. These data indicate that PPCM is mainly a vascular disease, caused by excess anti-angiogenic signalling in the peripartum period. The data also explain how late pregnancy poses a threat to cardiac homeostasis, and why pre-eclampsia and multiple gestation are important risk factors for the development of PPCM.

1 April 2015 in Hypertension
Verified
Journal Article
Closed access
PDF file
DPDafina Pruthi
Dafina Pruthi
EKEliyahu V. Khankin
Eliyahu V. Khankin
RBRobert M. Blanton
Robert M. Blanton
MAMark Aronovitz
Mark Aronovitz
SBSuzanne D. Burke
Suzanne D. Burke
IJIris Z. Jaffe
Iris Z. Jaffe
Cardiovascular disease (CVD) remains the leading killer of women in developed nations. One sex-specific risk factor is preeclampsia, a syndrome of hypertension and proteinuria that complicates 5% of pregnancies. Although preeclampsia resolves after delivery, exposed women are at increased long-term risk of premature CVD and mortality. Pre-existing CVD risk factors are associated with increased risk of developing preeclampsia but whether preeclampsia merely uncovers risk or contributes directly to future CVD remains a critical unanswered question. A mouse preeclampsia model was used to test the hypothesis that preeclampsia causes an enhanced vascular response to future vessel injury. A preeclampsia-like state was induced in pregnant CD1 mice by overexpressing soluble fms-like tyrosine kinase-1, a circulating antiangiogenic protein that induces hypertension and glomerular disease resembling human preeclampsia. Two months postpartum, soluble fms-like tyrosine kinase-1 levels and blood pressure normalized and cardiac size and function by echocardiography and renal histology were indistinguishable in preeclampsia-exposed compared with control mice. Mice were then challenged with unilateral carotid injury. Preeclampsia-exposed mice had significantly enhanced vascular remodeling with increased vascular smooth muscle cell proliferation (180% increase; P <0.01) and vessel fibrosis (216% increase; P <0.001) compared with control pregnancy. In the contralateral uninjured vessel, there was no difference in remodeling after exposure to preeclampsia. These data support a new model in which vessels exposed to preeclampsia retain a persistently enhanced vascular response to injury despite resolution of preeclampsia after delivery. This new paradigm may contribute to the substantially increased risk of CVD in woman exposed to preeclampsia.

1 April 2014 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
KHKim M. Holwerda
Kim M. Holwerda
SBSuzanne D. Burke
Suzanne D. Burke
MFMarijke M. Faas
Marijke M. Faas
ZZZsuzsanna Kinga Zsengeller
Zsuzsanna Kinga Zsengeller
ISIsaac E. Stillman
Isaac E. Stillman
ALA. Titia Lely
A. Titia Lely
Soluble fms-like tyrosine kinase 1 (sFlt1), a circulating antiangiogenic protein, is elevated in kidney diseases and contributes to the development of preeclampsia. Hydrogen sulfide is a vasorelaxant and proangiogenic gas with therapeutic potential in several diseases. Therefore, we evaluated the potential therapeutic effect and mechanisms of action of hydrogen sulfide in an animal model of sFlt1-induced hypertension, proteinuria, and glomerular endotheliosis created by adenovirus-mediated overexpression of sFlt1 in Sprague-Dawley rats. We injected sFlt1-overexpressing animals intraperitoneally with the hydrogen sulfide–donor sodium hydrosulfide (NaHS) (50 µmol/kg, twice daily) or vehicle (n=7 per group). Treatment with NaHS for 8 days significantly reduced sFlt1-induced hypertension, proteinuria, and glomerular endotheliosis. Measurement of plasma protein concentrations with ELISA revealed a reduction of free plasma sFlt1 and an increase of free plasma vascular endothelial growth factor (VEGF) after treatment with NaHS. Renal VEGF-A mRNA expression increased significantly with NaHS treatment. In vitro, NaHS was proangiogenic in an endothelial tube assay and attenuated the antiangiogenic effects of sFlt1. Stimulation of podocytes with NaHS resulted in both short-term VEGF release (120 minutes) and upregulation of VEGF-A mRNA levels (24 hours). Furthermore, pretreatment of mesenteric vessels with a VEGF receptor 2–neutralizing antibody significantly attenuated NaHS-induced vasodilation. These results suggest that hydrogen sulfide ameliorates sFlt1-induced hypertension, proteinuria, and glomerular endotheliosis in rats by increasing VEGF expression. Further studies are warranted to evaluate the role of hydrogen sulfide as a novel therapeutic agent for vascular disorders such as preeclampsia.

1 March 2010 in Hypertension
Verified
Journal Article
Closed access
PDF file
SBSuzanne D. Burke
Suzanne D. Burke
VBValérIe F. Barrette
ValérIe F. Barrette
JBJuares Bianco
Juares Bianco
JTJulie G. Thorne
Julie G. Thorne
AYAureo T. Yamada
Aureo T. Yamada
BCB. Anne Croy
B. Anne Croy
Maternal cardiovascular adaptations occur in normal pregnancy, systemically, and within the uterus. In humans, gestational control of blood pressure is clinically important. Transient structural remodeling of endometrial spiral arteries normally occurs in human and mouse pregnancies. In mice, this depends on uterine natural killer cell function. Using normal and immune-deficient mice, we asked whether spiral artery remodeling critically regulates gestational mean arterial pressure and/or placental growth. Radiotelemetric transmitters were implanted in females and hemodynamic profiles to a dietary salt challenge and to pregnancy were assessed. Implantation sites from noninstrumented females were used for histological morphometry. Both normal and immune-deficient mice had normal sensitivity to salt and showed similar 5-phase gestational patterns of mean arterial pressure correlating with stages of placental development, regardless of spiral artery modification. After implantation, mean arterial pressure declined during the preplacental phase to reach a midgestation nadir. With gestation day 9 opening of placental circulation, pressure rose, reaching baseline before parturition, whereas heart rate dropped. Heart rate stabilized before parturition. Placental sizes deviated during late gestation when growth stopped in normal mice but continued in immune-deficient mice. As an indication of the potential for abnormal hemodynamics, 2 pregnant females delivering dead offspring developed late gestational hypertension. This study characterizes a dynamic pattern of blood pressure over mouse pregnancy that parallels human gestation. Unexpectedly, these data reveal that spiral artery remodeling is not required for normal gestational control of blood pressure or for normal placental growth.

26 June 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SRSarosh Rana
Sarosh Rana
ARAugustine Rajakumar
Augustine Rajakumar
CGCarl Geahchan
Carl Geahchan
SSSaira Salahuddin
Saira Salahuddin
ACAna Sofia Cerdeira
Ana Sofia Cerdeira
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Up‐regulation of placental soluble fms‐like tyrosine kinase 1 (sFlt1) contributes to the pathogenesis of preeclampsia. To evaluate novel upstream pathways that regulate placental sFlt1 production, we screened a library of natural compounds ( n =502) in human placental cell lines. Here, we report 3 compounds in the cardiac glycoside family, ouabain, gitoxigenin, and digitoxin, that inhibit placental sFlt1 production at nanomolar concentrations in vitro. We further characterized ouabain and demonstrated that it inhibits sFlt1 mRNA and protein expression in human placental cytotrophoblasts and explant cultures in a dose‐ and time‐dependent manner. Ouabain down‐regulated sFlt1 production by inhibiting hypoxia‐inducible factor 1 (HIF‐1α) protein expression in the placenta. Furthermore, we found that phosphorylation of heat‐shock protein 27 (HSP27) was necessary for ouabain to inhibit HIF‐1α translation. In a rat model of pregnancy‐induced hypertension, ouabain reduced mean arterial pressure and enhanced placental HSP27 phosphorylation without any adverse effects on pups. Further studies are needed to explore the usefulness of targeting HIF‐1α/HSP27 pathway in preeclampsia.—Rana, S., Rajakumar, A., Geahchan, C., Salahuddin, S., Cerdeira, A. S., Burke, S. D., George, E. M., Granger, J. P., Karumanchi, S., A. Ouabain inhibits placental sFlt1 production by repressing HSP27‐dependent HIF‐1α pathway. FASEB J. 28, 4324–4334 (2014). www.fasebj.org

10 May 2010 in American Journal of Reproductive Immunology
Verified
Journal Article
Open access
PDF file
SBSuzanne D. Burke
Suzanne D. Burke
VBValerie F. Barrette
Valerie F. Barrette
JGJonathan Gravel
Jonathan Gravel
ACAlexandra L. I. Carter
Alexandra L. I. Carter
KHKota Hatta
Kota Hatta
BCB. Anne Croy
B. Anne Croy
Citation Burke SD, Barrette VF, Gravel J, Carter ALI, Hatta K, Zhang J, Chen Z, Leno‐Durán E, Bianco J, Leonard S, Murrant C, Adams MA, Anne Croy B. Uterine NK cells, spiral artery modification and the regulation of blood pressure during mouse pregnancy. Am J Reprod Immunol 2010Reproductive success in mammals involves coordinated changes in the immune and cardiovascular as well as in the neuroendocrine and reproductive systems. This review addresses studies that identify potential links for NK cells and T cells with the local and systemic cardiovascular adaptations of pregnancy. The studies reviewed have utilized immunohistochemisty and in vivo analyses of vascular parameters by ultrasound, chronic monitoring of hemodynamics via radiotelemetric recording and intravital microscopy. At the uterine level, functional subsets of uterine natural killer cells were identified. These included subsets expressing molecules important for vasoregulation, in addition to those previously identified for angiogenesis. Spiral arteries showed conducted responses that could account for conceptus control of vasoactivity and mouse gestational blood pressure 5‐phase pattern. Vascular immunology is an emerging transdisciplinary field, critical for both reproductive immunology and cardiovascular disease.